Sarepta Therap

Q2 FY2026 EarningsQ2 FY26 beat consensus on the top line with total revenue of $401.3M vs. $364.9M expected, driven by robust collaboration revenue from Roche. However, profitability missed expectations significantly due to a $39M one-time litigation contingency charge and increased Roche-related manufacturing write-offs, resulting in a GAAP EPS loss of -$0.05 vs. an expected gain of $0.20. While net product sales declined 36% YoY following safety-related label restrictions for ELEVIDYS, the company maintained a strong cash position of $945M and implemented strategic restructuring to reduce long-term operating costs.